Effects of guanine, inosine, and xanthine nucleotides on beta(2)-adrenergic receptor/G(s) interactions: evidence for multiple receptor conformations.
The aim of our study was to examine the effects of different purine nucleotides [GTP, ITP, and xanthosine 5'-triphosphate (XTP)] on receptor/G protein coupling. As a model system, we used a fusion protein of the beta(2)-adrenergic receptor and the alpha subunit of the G protein G(s). GTP was more potent and efficient than ITP and XTP at inhibiting ternary complex formation and supporting adenylyl cyclase (AC) activation. We also studied the effects of several beta(2)-adrenergic receptor ligands on nucleotide hydrolysis and on AC activity in the presence of GTP, ITP, and XTP. The efficacy of agonists at promoting GTP hydrolysis correlated well with the efficacy of agonists for stimulating AC in the presence of GTP. This was, however, not the case for ITP hydrolysis and AC activity in the presence of ITP. The efficacy of ligands at stimulating AC in the presence of XTP differed considerably from the efficacies of ligands in the presence of GTP and ITP, and there was no evidence for receptor-regulated XTP hydrolysis. Our findings support the concept of multiple ligand-specific receptor conformations and demonstrate the usefulness of purine nucleotides as tools to study conformational states of receptors.
Howard Hughes Medical Institute, Stanford University Medical School, Stanford, California, USA.
R
R
Seifert
U
U
Gether
K
K
Wenzel-Seifert
B K
BK
Kobilka
D000255:Adenosine Triphosphate / Q000494:pharmacology; D000262:Adenylyl Cyclases / Q000378:metabolism; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D002478:Cells, Cultured; D020558:GTP Phosphohydrolases / Q000378:metabolism; D019205:GTP-Binding Protein alpha Subunits, Gs / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D006160:Guanosine Triphosphate / Q000494:pharmacology; D006868:Hydrolysis; D007293:Inosine Triphosphate / Q000494:pharmacology; D007313:Insecta; D007545:Isoproterenol / Q000494:pharmacology; D007700:Kinetics; D008024:Ligands; D011412:Propanolamines / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D011487:Protein Conformation; D011685:Purine Nucleotides / Q000494:pharmacology*; D011755:Pyrophosphatases / Q000378:metabolism; D018343:Receptors, Adrenergic, beta-2 / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D012265:Ribonucleotides / Q000494:pharmacology; D000097630:Inosine Triphosphatase
D000255:Adenosine Triphosphate; D000262:Adenylyl Cyclases; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D020558:GTP Phosphohydrolases; D019205:GTP-Binding Protein alpha Subunits, Gs; D006160:Guanosine Triphosphate; D007293:Inosine Triphosphate; D007545:Isoproterenol; D008024:Ligands; D011412:Propanolamines; D011685:Purine Nucleotides; D011755:Pyrophosphatases; D018343:Receptors, Adrenergic, beta-2; D011993:Recombinant Fusion Proteins; D012265:Ribonucleotides; D000097630:Inosine Triphosphatase; C026777:ICI 118551; C065326:xanthosine 5'-triphosphate